Positron Emission Tomography and Thyroid Cancer

PET Clinics

Volumn 2, Issue 3, 2007, Pages 295-304

  Urhan, Muammer ^a   Mavi, Ayse ^b   Alavi, Abass ^c   Nanni, Cristina ^d  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

18 F fluorodeoxyglucose; Differentiated thyroid cancer; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 124; RADIOACTIVE IODINE;

CANCER CELL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER THERAPY; CELL DEDIFFERENTIATION; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LUNG METASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REVIEW; SEROLOGY; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 64749085939     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.04.004     Document Type: Review

References (91)

1. Parkin M.D., Pisani P., and Ferlay J. Global cancer statistics. Cancer J Clin 49 (1999) 33-64
2. Hundahl S.A., Fleming I.D., Fremgen A.M., et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US,'85-'95. Cancer 83 (1998) 2638-2648
3. Ron E., Kleinerman R.A., Boice Jr. J.D., et al. A population based case-control study of thyroid cancer. J Natl Cancer Inst 79 (1987) 1-12
4. Shore R.E. Issues and epidemiologic evidence regarding radiation-induced thyroid cancer. Radiat Res 131 (1992) 98-111
5. Fraker D.L., Skarulis M., and Livolsi V. Thyroid tumors. In: De-Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer-principles and practice of oncology. 5th edition (1997), Lippincott-Raven, Philadelphia 1629-1651
6. Hundahl S.A. Perspective: National Cancer Institute summary about estimated exposures and thyroid doses received from iodine-131 in fallout after Nevada atmospheric nuclear bomb tests. Cancer J Clin 48 (1998) 285-298
7. Hamilton T.E., van Belle G., and LoGerfo J.P. Thyroid neoplasia in Marshall islanders exposed to nuclear fallout. JAMA 258 (1987) 629-636
8. Nikiforov Y., and Gnepp D.R. Pediatric thyroid cancer after the Chernobyl disaster. Cancer 74 (1994) 748-766
9. Ron E., Lubin J.H., Shore R.E., et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141 (1995) 259-277
10. Schneider A.B., and Ron E. Pathogenesis. In: Braverman L.E., and Utiger R.D. (Eds). Werner and Ingbars the thyroid: a fundamental and clinical text. 7th edition (1996), Lippincott-Raven, Philadelphia 902-906
11. Francheschi S., Boyle P., Maisonneuve P., et al. The epidemiology of thyroid carcinoma. Crit Rev Oncog 4 (1993) 25-52
12. Chung J.-K., So Y., Lee J.S., et al. Value of FDG-PET in papillary thyroid carcinoma with negative 131-I whole-body scan. J Nucl Med 40 (1999) 986-992
13. Grunwald F., Menzel C., Bender H., et al. Comparison of F-18 FDG-PET with iodine-131 and Tc-99m-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7 (1997) 327-335
14. Dietlein M., Scheidhauer K., Voth E., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24 (1997) 1342-1348
15. Grunwald F., Schomburg A., Bender H., et al. Fluorine-18 fluorodexyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23 (1996) 312-319
16. Anderson G.S., Fish S., Nakhoda K., et al. Comparison of I-123 and I-131 600 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report. Clin Nucl Med 28 (2003) 93-96
17. Urhan M., Dadparvar S., Mavi A., et al. I-123 As a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with i-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging 34 7 (2007) 1012-1017
18. Dai G., Levy O., and Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 379 (1996) 458-460
19. Casara D., Rubello D., Saladini G., et al. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative I-131 whole body scintigraphy: importance of Tc-99m MIBI scan combined with high resolution neck US. Tumori 85 (1999) 120-125
20. Baudin E., Schulumberger M., Lumbroso J., et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scans. J Clin Endocrinol Metab 81 (1996) 2541-2544
21. Burman K.D., Anderson J.H., Wartofsky L., et al. Management of patients with thyroid carcinoma: application of Tl-201 scintigraphy and magnetic resonance imaging. J Nucl Med 31 (1990) 1958-1964
22. Dadparvar S., Chevres A., Thulchinsky M., et al. Clinical Utility of Tc-99m MIBI imaging in differentiated thyroid carcinoma: comparison with Tl-201 and I-131 Na scintigraphy and serum thyroglobulin quantitation. Eur J Nucl Med 22 (1995) 1330-1338
23. Warburg O. The metabolism of tumors (1930), Constable, London
24. Lowe V.J., Fletcher J.W., Gobar L., et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16 3 (1998) 1075-1084
25. Hall N., and Kloos R.T. PET Imaging in differentiated thyroid cancer: where does it fit and how do we use it?. Arq Bras Endocrinol Metabol 51 5 (2007) 793-805
26. Coleman P.M., Babb P., Damiecky P., et al. Cancer survival trends in England and Wales 1971-1995: deprivation and NHS region series SMPS no: 61 (1999), Stationary Office, London p. 471-8
27. Krishnamurthy S., Bedi D.G., and Caraway N.P. Ultrasound-guided fine-needle aspiration of the thyroid bed. Cancer 25 (2001) 199-205
28. Kang K.W., Kim S.K., Kang H.S., et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88 (2003) 4100-4104
29. Kim T.Y., Kim W.B., Ryu J.S., et al. 18Ffluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 115 (2005) 1074-1078
30. Chen Y.K., Ding H.J., Chen K.T., et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 25 (2005) 1421-1426
31. Choi J.Y., Lee K.S., Kim H.J., et al. Focal thyroid lesions incidentally identified by integrated 18FFDG PET/CT: clinical significance and improved characterization. J Nucl Med 47 (2006) 609-615
32. Adler L.P., and Bloom A.D. Positron emission tomography of thyroid masses. Thyroid 3 (1993) 195-200
33. Bloom A.D., Adler L.P., and Shuck J.M. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 114 (1993) 728-734
34. Scott G.C., Meier D.A., and Dickinson C.Z. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 36 (1995) 1843-1845
35. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 2 (2006) 109-141
36. Geus-Oei L.F., Pieters G.F., Bonenkamp J.J., et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 47 (2006) 770-775
37. Kim J.M., Ryu J.S., Kim T.Y., et al. 18F-luorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 92 5 (2007) 1630-1634
38. Kresnik E., Gallowitsch H.J., Mikosch P., et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 133 (2003) 294-299
39. Joensuu H., and Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 28 (1987) 910-914
40. Feine U., Lietzenmayer R., Hanke J.P., et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
41. Grunwald F., Kalicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26 (1999) 1547-1552
42. Wang W.P., Macapinlac H., Larson S.M., et al. F-18 -2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic I-131 whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84 (1999) 2291-2302
43. Frilling A., Tecklenborg K., Görges R., et al. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234 6 (2001) 804-811
44. Shiga T., Tsukamoto E., Nakada K., et al. Comparison of 18-F-FDG, 131-I-Na and 201-Tl in diagnosis of recurrent or metastatic thyroid carcinoma. J Nucl Med 42 (2001) 414-419
45. Yeo J.S., Chung J.K., So Y., et al. F-18-fluoro-deoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 23 (2001) 94-103
46. Schluter B., Bohuslavizki K.H., Beyer W., et al. Impact of FDG-PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42 (2001) 71-76
47. Helal B.O., Merlet P., Toubert M.E., et al. Clinical impact of (18)F-FDG-PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
48. Plotkin M., Hautzel H., Krause B.J., et al. Implication of 2-(18)fluor-2-deoxyglucose positron emission tomography in the follow-up of Hurtle cell thyroid cancer. Thyroid 12 (2002) 155-161
49. Sarlis N.J., Gourgiotis I., Guthrie L.C., et al. In-111 DTPA- octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging. Clin Nucl Med 28 (2003) 208-217
50. Chen Y.K., Liu F.Y., Yen R.F., et al. Compare FDG-PET and Tc-99m tetrafosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 10 (2003) 835-839
51. Hung M.C., Wu H.S., Kao C.H., et al. F-18-fluoro-deoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole-body scan. Endocr Res 29 (2003) 169-175
52. Gabriel M., Froehlich F., Decristoforo C., et al. 99mTc-EDDA/HYNIC-TOC and (18)F-FDG in thyroid cancer patients with negative (131)I whole-body scans. Eur J Nucl Med Mol Imaging 31 (2004) 330-341
53. Nahas Z., Goldenberg D., Fakhry C., et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115 (2005) 237-243
54. Pryma D.A., Schoder H., Gonen M., et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurtle cell thyroid cancer. J Nucl Med 47 8 (2006) 1260-1266
55. Shammas A., Degirmenci B., Mountz J.M., et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48 2 (2007) 221-226
56. Salvatore B., Paone G., Klain M., et al. Fluorodeoxyglucose positron emission tomography/computed tomography in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and 131-I ablation. Q J Nucl Med Mol Imaging 51 (2007) 1-7
57. Iagaru A., Kalinyak J.E., and McDougall I.R. F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32 (2007) 690-695
58. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging 34 (2007) 487-495
59. Azadian A., Rosen I.B., Walfish P.G., et al. Management consideration in Hurtle cell carcinoma. Surgery 118 (1995) 711-714
60. Shaha A.R., Ferlito A., and Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL J Otorhinolaryngol Relat Spec 63 (2001) 243-249
61. Yen T.C., Lin H.D., Lee C.H., et al. The role of Technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurtle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201whole-body scans. Eur J Nucl Med 21 (1994) 980-983
62. Jadvar H., and Fishman A.J. Evaluation of rare tumors with (F-18)fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 2 (1999) 153-158
63. McDougall IR, Jadvar H, Segall G. PET scan in patients with suspected recurrent thyroid cancer. Presented at thyroid one. Thyroid Cancer Pathogenesis, Diagnosis including PET, and treatment. International Symposium. Linz, Austria, October 7-10, 1998. Thyroid 1998;8:1222, Abstract.
64. Zimmer L.A., McCook B., Meltzer C., et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolaryngol Head Neck Surg 128 (2003) 178-184
65. Wang W., Larson S.M., Fazzari M., et al. Prognostic value of 18-F-Fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85 (2000) 1107-1113
66. Schonberger J., Ruschhoff J., Grimm D., et al. Glucose transporter-1 gene expression is related to thyroid neoplasm with an unfavorable prognosis: an immunohistohemical study. Thyroid 12 (2002) 747-754
67. Giammarile F., Hafdi Z., Bournaud C., et al. Is 18F -2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?. Eur J Endocrinol 149 (2003) 293-300
68. Lowe V.J., Mullan B.P., Hay I.D., et al. 18F-FDG PET of patients with Hurtle-cell carcinoma. J Nucl Med 44 (2003) 1402-1406
69. Schluter B., Grimm-Riepe C., Beyer W., et al. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer. Langenbecks Arch Surg 383 (1998) 187-189 692
70. Muros M.A., Llamas-Elvira J.M., Ramirez-Navarro A., et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179 (2000) 457-461
71. Pacini F., Schlumberger M., Dralle H., et al. European Consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J endocrinol 154 (2006) 787-803
72. Haraguchi K., Rani C.S., and Field J.B. Effects of thyrotropin, carbachol, and protein kinase-C stimulators on glucose transport and glucose oxidation by primary cultures of dog thyroid cells. Endocrinology 123 (1988) 1288-1295
73. Filetti S., Damante G., and Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 120 (1987) 2576-2581
74. Hosaka Y., Tawata M., Kurlhara A., et al. The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expression in cultured rat thyroid cells by thyrotropin. Endocrinology 131 (1992) 159-165
75. Sisson J.C., Ackermann R.J., Meyer M.A., et al. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer. Implications for diagnosis and therapy. J Clin Endocrinol Metab 77 (1993) 1090-1094
76. Eustatia-Rytten C.F., Smit J.W., Romijn J.A., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61 (2004) 61-74
77. van Tol K.M., Jager P.L., Piers D.A., et al. Better yield of (18)fluo-fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 715 12 (2002) 381-387
78. Chin B.B., Patel P., Cohade C., et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89 (2004) 91-95
79. Moog F., Linke R., Manthey N., et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41 (2000) 1989-1995
80. Petrich T., Borner A.R., Weckesser E., et al. Follow-up of thyroid cancer patients using rhTSH: preliminary results. Nuklearmedizin 40 (2001) 7-14
81. Lambrecht R.M., Woodhouse N., Phillips R., et al. Investigational study of iodine-124 with a positron camera. Am J Physiol Imaging 3 (1988) 197-200
82. Pentlow K.S., Graham M.C., Lambrecht R.M., et al. Quantative imaging of iodine-124 with PET. J Nucl Med 37 (1996) 1557-1562
83. Frey P., Townsend D., Flattet A., et al. Tomographic imaging of the human thyroid using 124I. J Clin Endocrinol Metab 63 (1986) 918-927
84. Schmidt D., Herzog H., Langen K.-J., et al. Glucose metabolism in thyroid cancer metastases. A pilot study using 18 fluoro-2-deoxy-D-glucose and positron emission tomography. Exp Clin Endocrinol 102 (1994) 51-54
85. Pacini F., Molinaro E., Castagna M.G., et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88 (2003) 3668-3673
86. Palmedo H., Bucerius J., Joe A., et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47 (2006) 616-624
87. Halpern B.S., Yeom K., Fueger B.J., et al. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol 62 (2007) 199-204
88. Ilgan S., Karacali{dotless}oglu A.O., Pabuscu Y., et al. Iodine-131 treatment and high resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 31 (2004) 825-830
89. Bar-Shalom R., Yefremov N., Guralnik L., et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44 (2003) 1200-1209
90. Nakamoto Y., Cohade C., Tatsumi M., et al. CT appearance of bone metastases detected with FDG-PET as part of the same PET/CT examination. Radiology 237 (2005) 627-634
91. Schirrmeister H., Guhlman A., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18-F PET. J Nucl Med 40 (1990) 1623-1629